The National Drug Law Enforcement Agency (NDLEA), has said Oyo and Lagos’s states remain the epicenter of drug abuse in Nigeria.
Buba Marwa, the NDLEA Chairman, made this revelation on Wednesday while speaking at a public lecture organized by United Action for Change (UAC) in Lagos.
According to NDLEA statistics, not less than 14.3 million Nigerians abuse drugs, with the southwest zone recording the highest prevalence.
The NDLEA Boss expressed concern over Nigeria’s drug statistics, saying the country is “number one in the use of cannabis”.
He said, “Nigeria’s drug statistics should give every one of us a sleepless night.
“Not less than 14.3 million Nigerians abuse drugs — Nigerians between the ages of 16 and 64 years. Among them, one in four drug users is female.
“Expectedly, cannabis is the most abused substance by Nigerians. What’s alarming, however, is that a staggering 10.6 million Nigerians abuse the use of cannabis.
“That number makes our country number one in the use of cannabis. Let’s ponder this for a moment; 10.6 million is more than the estimated population of Botswana and Lesotho combined.
“Most of the abusers first started at the age of 19, and the highest level of usage is concentrated in youth between 25 and 29.
“The highest abuse of drugs is reported in the southern geopolitical zone, with the south-west recording the highest prevalence with over four million Nigerians engaging in the use of various drugs.
“In this regard, the Lagos-Oyo axis is the epicenter of drug abuse in Nigeria.”
There was chaos in the Eleyele area of Ile-Ife, Osun State, on Friday evening as…
In recent years, the rise of social media platforms such as X, Instagram and TikTok…
A High Court in Benin, on Friday, annulled the suspension of the chairmen and vice…
A Madrid court on Friday sentenced Rodrigo Rato, the former head of the International Monetary…
Three police officers and a female suspect have been confirmed dead in a tragic road…
The Court of Appeal in Abuja has ordered MTN Nigeria Communications Limited to pay N15…
This website uses cookies.